# OnCo record bcd-217 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bcd-217/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bcd-217" ;
  schema:name "BCD-217"@en ;
  schema:alternateName "nurulimab+prolgolimab"@en ;
  schema:description "BCD-217 is an experimental investigational agent whose form is not stated in the registry from Biocad in phase 3 trials for melanoma, aimed at PD-1 and CTLA-4."@en ;
  schema:url <https://onco.cc/drugs/bcd-217/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=BCD-217>, <https://biocad.ru/products> ;
  onco:status "phase-3" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:companies <https://onco.cc/companies/biocad/> ;
  onco:trials <https://onco.cc/trials/nct05732805/>, <https://onco.cc/trials/nct05751928/> .